X2S Stock Overview
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.50 |
| 52 Week High | HK$2.72 |
| 52 Week Low | HK$1.84 |
| Beta | 0.86 |
| 11 Month Change | 6.93% |
| 3 Month Change | 22.14% |
| 1 Year Change | 11.91% |
| 33 Year Change | 19.06% |
| 5 Year Change | -16.14% |
| Change since IPO | 41.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| X2S | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 1.1% | 0.2% |
| 1Y | 11.9% | 16.5% | 8.5% |
Return vs Industry: X2S underperformed the German Healthcare industry which returned 16.5% over the past year.
Return vs Market: X2S exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| X2S volatility | |
|---|---|
| X2S Average Weekly Movement | 6.1% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: X2S has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: X2S's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 113,635 | Wanyong Lian | www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
| X2S fundamental statistics | |
|---|---|
| Market cap | €7.88b |
| Earnings (TTM) | €1.14b |
| Revenue (TTM) | €77.83b |
6.9x
P/E Ratio0.1x
P/S RatioIs X2S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X2S income statement (TTM) | |
|---|---|
| Revenue | CN¥590.35b |
| Cost of Revenue | CN¥543.16b |
| Gross Profit | CN¥47.18b |
| Other Expenses | CN¥38.53b |
| Earnings | CN¥8.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.77 |
| Gross Margin | 7.99% |
| Net Profit Margin | 1.47% |
| Debt/Equity Ratio | 78.1% |
How did X2S perform over the long term?
See historical performance and comparison